Genzyme Corp. and the FDA’s Cardiovascular and Renal Products Advisory Committee will meet to consider the use of phosphate binders in patients with chronic kidney disease (CKD) who are not on dialysis.     The FDA has also requested that Shire and Fresenius — companies that currently market phosphate binders for patients on dialysis — provide information that will help the agency make a decision regarding the use of phosphate binders in CKD.          In a briefing packag...